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Drug-resistant *Shigella* causes 27,000 infections per year in the United States ([@B1]). Symptoms of *Shigella* infection can include mild to severe diarrhea and bloody diarrhea, and in some individuals, infection can progress to serious complications, including reactive arthritis. Outbreaks of drug-resistant *Shigella sonnei* are increasingly occurring in the United States ([@B2][@B3][@B4]).

We report here four high-quality draft whole-genome sequence assemblies generated by PacBio sequencing and verified using the strain's whole-genome map (WGM). The sequenced strains were isolated between 2014 and 2015 and are from separate outbreaks in different states.

*Shigella* genomic DNA was extracted according to the manufacturer's protocol (Archive Pure; 5 Prime, Gaithersburg, MD). The DNA was sheared to 20-kb fragments using needle shearing and were size selected utilizing BluePippin. DNA fragments were used to generate large SMRTbell libraries using the standard library protocols of the Pacific Biosciences DNA template preparation kit (Menlo Park, CA). One single-molecule real-time (SMRT) cell was used to sequence each isolate. Finished libraries were bound to proprietary P6v2 polymerase and sequenced on a PacBio RSII sequencer using C4 chemistry for 360-min movies. Sequence reads were filtered and assembled *de novo* utilizing the PacBio Hierarchical Genome Assembly Process version 3 ([@B5]). WGMs were generated according to the OpGen protocol. The sequence order in the resulting PacBio assemblies was verified using restriction enzymes NcoI and AflII and WGMs.

The accession numbers and assembly metrics for each draft genome sequence are listed in [Table 1](#tab1){ref-type="table"}. A single chromosomal contig was generated for each isolate of 51.0% G+C content and 78 to 158× coverage, and was determined to be circular, with overlapping ends that were subsequently trimmed from one end. The plasmid contigs associated with these isolates had 23 to 79× coverage, did not have overlapping ends, and were not closed. These sequences were annotated with the NCBI Prokaryotic Genome Annotation Pipeline ([@B6]).

###### 

Accession numbers and assembly metrics of the four annotated *Shigella* draft whole-genome sequences

  *Shigella* isolate   NCBI accession no.                                                                                                     Genome size (bp)   Associated plasmid size(s) (bp)   Phenotypic resistance or Azm non-wild type[^a^](#ngtab1.1){ref-type="table-fn"}
  -------------------- ---------------------------------------------------------------------------------------------------------------------- ------------------ --------------------------------- ---------------------------------------------------------------------------------
  2015AM-1099          [CP021144](https://www.ncbi.nlm.nih.gov/nuccore/CP021144)                                                              4,935,567          None                              S Su T Cot
  2015C-3566           [CP022457](https://www.ncbi.nlm.nih.gov/nuccore/CP022457), [CP022458](https://www.ncbi.nlm.nih.gov/nuccore/CP022458)   4,893,408          55,820                            S
  2015C-3794           [CP022455](https://www.ncbi.nlm.nih.gov/nuccore/CP022455), [CP022456](https://www.ncbi.nlm.nih.gov/nuccore/CP022456)   4,818,812          87,791                            A Cx Cip Nal S Su T Cot
  2015C-3807           [CP022459](https://www.ncbi.nlm.nih.gov/nuccore/CP022459)--[CP022461](https://www.ncbi.nlm.nih.gov/nuccore/CP022461)   4,794,648          67,988, 66,524                    A Azm S Su T Cot

Phenotypic resistance codes: S, streptomycin; Su, sulfisoxazole; T, tetracycline; Cot, trimethoprim-sulfamethoxazole; A, ampicillin; Cx, ceftriaxone; Cip, ciprofloxacin; Nal, nalidixic acid; Azm, azithromycin.

Antimicrobial susceptibility testing was performed by broth microdilution (Sensititre, Cleveland, OH) and used to determine the MICs for 14 antimicrobial agents: ampicillin, amoxicillin-clavulanic acid, azithromycin, cefoxitin, ceftriaxone, chloramphenicol, ciprofloxacin, gentamicin, meropenem, nalidixic acid, streptomycin, sulfisoxazole, tetracycline, and trimethoprim-sulfamethoxazole ([@B7]). Resistance was defined by the Clinical and Laboratory Standards Institute (CLSI) interpretive standards, when available ([@B8]). For streptomycin, where no CLSI interpretive criteria for human isolates exist, resistance was defined as ≥64 mg/liter.

Accession number(s). {#s1}
--------------------

The annotated whole-genome *S. sonnei* sequences have been deposited in DDBJ/ENA/GenBank under the accession numbers [CP022455](https://www.ncbi.nlm.nih.gov/nuccore/CP022455) to [CP022461](https://www.ncbi.nlm.nih.gov/nuccore/CP022461) and [CP021144](https://www.ncbi.nlm.nih.gov/nuccore/CP021144) (see [Table 1](#tab1){ref-type="table"}). The version described in this paper is the first version.
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